AI Digital Therapeutics Anti-Depression Digital Prescription Platform

📌 Background

Generative AI empowers psychotherapy, with companies like Wangli Technology securing medical device certification in 2026 and ushering in a new era of digital prescriptions. Given the massive base of patients with mental and psychological disorders and the severe shortage of high-quality psychological counseling supply, clinically validated digital therapeutics have become an efficient new intervention solution. The demand gap in healthcare has existed for a long time, but regulatory review and clinical evidence are unavoidable prerequisite barriers, and payers only pay for proven efficacy and cost savings; talking about revenue before obtaining certification is premature. Operating figures in the text are subject to company financial reports or official calibers, and self-reported data by merchants are not independently verified and adopted.

👤 Target Customers

Patients with various mild to moderate depression and anxiety disorders, with digital prescriptions issued by psychiatrists and paid for by hospitals or patients. Whether prescriptions can be continuously issued and whether patients complete the treatment course directly determines the stability of this revenue line; the actual deployed patient scale is subject to hospital-side conversion data (scale not yet verified).

💰 Revenue Streams

1) Institutional Licensing: Charging medical institutions licensing fees for digital prescription software per treatment course, settled by treatment course milestones; 2) Commercial Insurance Revenue Sharing: Sharing revenue with commercial health insurance under a pay-for-performance model, with the sharing ratio depending on the payment plan provided by the insurer; 3) Patient Subscription: Directly charging patients monthly subscription fees, with the number of paying users and renewal rates determining the stability of this path; 4) Follow-up and Renewal: Charging follow-up management and renewal service fees per treatment course or subscription cycle, which is an opportunistic item, and the revenue volume of this part has not yet been publicly disclosed.

🧮 Cost Structure

Lengthy clinical trials and regulatory certification costs, AI model training and data privacy compliance costs, and psychiatrist network channel expansion fees. The most rigid costs here are the staffing of clinical and compliance teams, as well as investments in training and inference computing power; expenses that fluctuate up and down with prescription volume are primarily doctor-side promotion and patient follow-up expenditures, which will be diluted as the scale of served patients expands.

🛡️ Moat

Medical device registration certificates issued by the National Medical Products Administration (NMPA), peer-reviewed clinical efficacy data, and prescription channel relationships with core tertiary psychiatric specialized hospitals, belonging to a data-accumulation type barrier.

🔑 Keys to Success

• Take the lead in obtaining the NMPA medical device registration certificate
• Establish a cooperative network of core psychiatric specialized hospitals
• Unblock the payment closed-loop of medical insurance or commercial insurance

⚠️ Risks

• Clinical effects falling short of expectations lead to hindered certification
• Slow progress in medical insurance or commercial insurance coverage leads to monetization difficulties

🏢 Cases

• 望里科技

📊 SWOT Analysis